We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.65 | 0.60 | 0.70 | 0.65 | 0.65 | 0.65 | 158,993 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 2k | -1.27M | -0.0032 | -2.03 | 2.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/11/2024 10:00 | What news from the show? | pwal | |
12/11/2024 21:24 | Just to let shareholders and prospective investors know that N4 Pharma will be presenting at Mello's 10-year anniversary show on Tuesday 19th November 2024 9am - 7pm. The Budget is out, Mello is in! To celebrate our 10 Year Anniversary, we have created a two-day investor conference that will include top quality keynote speakers including but not limited to Peter Pereira Gray, Paul Hill, Ben Rogoff, Rosemary Banyard and Gervais Williams. Also featuring panel sessions such as our popular Mello BASH (Buy, Avoid, Sell, Hold) with professional investors and analysts such as Leon Boros, Mark Simpson and Paul Scott. There will be over 40 exhibiting companies and over 60 presentations from companies such as The Property Franchise Group, Time Finance, Brave Bison, Mortgage Advice Bureau, Aeorema and many more! Get 50% off your ticket with code MMTADVFN50. Tickets are still available: | mello2024 | |
12/11/2024 12:27 | The price has moved because of the large spread. Hopefully that will close up and we can see a real rise. | pwal | |
11/11/2024 13:49 | Who thinks N4P can hit 1p before the end of the year? | pwal | |
08/11/2024 12:40 | Let's hear what they have to say on the 19th. | pwal | |
07/11/2024 22:34 | Just to let shareholders and prospective investors know that N4 Pharma will be presenting at Mello's 10-year anniversary show on Tuesday 19th November 2024 9am - 7pm. The Budget is out, Mello is in! To celebrate our 10 Year Anniversary, we have created a two-day investor conference that will include top quality keynote speakers including but not limited to Peter Pereira Gray, Paul Hill, Ben Rogoff, Rosemary Banyard and Gervais Williams. Also featuring panel sessions such as our popular Mello BASH (Buy, Avoid, Sell, Hold) with professional investors and analysts such as Leon Boros, Mark Simpson and Paul Scott. There will be over 40 exhibiting companies and over 60 presentations from companies such as The Property Franchise Group, Time Finance, Brave Bison, Mortgage Advice Bureau, Aeorema and many more! Get 50% off your ticket with code MMTADVFN50. Tickets are still available: | mello2024 | |
06/11/2024 15:47 | McNulty tends to be a good judge on timing when buying distressed stocks set for a substantial rebound, in my view. I've admittedly re-purchased too. | davethechef | |
06/11/2024 13:18 | More positive news? Am I the only one that thinks the only real news we have had is the approval promised in September, has been pushed back to early next year. And according to Nige it wont really matter if we dont get it! Priceless. The rest is all PR and hot air as usual. It sounds promising but there is still no actual firm commitment about anything else. So get on with it Nigel and bag us a deal, or maybe that new exec will come up with something. The only thing that will shift the share price meaningfully is a partner laying out some cash. That is the reality. | earwacks | |
06/11/2024 12:21 | Need more positive news! | pwal | |
05/11/2024 17:33 | McNulty has bought back in | dplewis1 | |
05/11/2024 11:55 | Lots of interest here at the moment. | pwal | |
04/11/2024 18:54 | The table illustrated other companies that had secured deals whilst at various stages. There were plenty in those two brokers lists that had secured deals at preclinical stage as well as phase 1 | johno1977 | |
04/11/2024 17:40 | Absolutely no chance of 30p next year! Have they put the Nuvec particles into people yet?!? Until they do there is a massive risk…. | nobbygnome | |
04/11/2024 17:37 | Yes it is all very exciting. IBD has come to the forefront now which is possibly their biggest market. The risk is still pretty high, but at least not a one trick pony as they explore other avenues. I think the failure of the Covid vaccine was seen possibly wrongly as a make or break situation and it spiralled as a result. The thing is the cash runway is not huge, so if nothing happens in next six months there will almost certainly be another call for cash. The cynic in me says this is what this current PR is all about to get the price up. The major change this year is The oral IBD drug and of course the competition threat. Should keep Nigel sharply focussed on a deal | earwacks | |
04/11/2024 17:27 | I just saw a pig flying past the window…. | nobbygnome | |
04/11/2024 17:27 | So target price range for 2025 is 10 to 30p!Now that's not bad. | pwal | |
31/10/2024 20:31 | Something stirring . People with inside info buying it would seem. Could just be SPAngel broker report recently, which at 22 pages is comprehensive. Other than the FDA approval not likely to happen till early 2025, not a lot we dont know. They have made a table of competitors ‘at a similar stage’ although I fail to see how companies that already have phase 1 license deals of a 100 million dollars can be comparable. This is something that seems to escape Nigel’s reasoning about being undervalued. So unless a deal is very close burning through a million a year for its existence hardly undervalues the company @ £2million market cap. | earwacks | |
25/10/2024 20:40 | No it’s a shocking lifestyle company which has got nowhere in many years. Everything is still preclinical despite the small fortune already spent… | nobbygnome | |
25/10/2024 16:06 | is this a good share | misoolisland | |
25/10/2024 16:06 | Nigel just needs to drag this out another couple of years to keep his pension contributions up then he'll be off. Of course he's going to say it's undervalued they'll need to do another placing at some point. Sorry Dave, if you're getting your valuations from a PDF marketing doc you've clearly learnt nothing over the years | dplewis1 | |
25/10/2024 12:49 | My point was Nigel has been saying that for ten years. It is quite possible that he will finally get some licensing agreement. If it was a slam dunk Americans would have waded in by now. Be a lot cheaper to buy this than do their own research. | earwacks |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions